Celldex Therapeutics, Inc. CLDXannounced the failure of its lead pipeline candidate, glembatumumab vedotin, in a phase IIb breast cancer study – METRIC. The candidate failed to meet the primary endpoint of progression-free survival (“PFS”) benefit over Roche’s RHHBYchemotherapy, Xeloda, in the treatment of metastatic triple-negative breast cancers that overexpress gpNMB.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться